- Home
- KRNT vs KNSA Comparison
KRNT vs KNSA Comparison
Compare KRNT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRNT
- KNSA
- Stock Information
- Founded
- KRNT 2002
- KNSA 2015
- Country
- KRNT Israel
- KNSA United Kingdom
- Employees
- KRNT N/A
- KNSA N/A
- Industry
- KRNT Industrial Machinery/Components
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- KRNT Industrials
- KNSA Health Care
- Exchange
- KRNT Nasdaq
- KNSA Nasdaq
- Market Cap
- KRNT 1.4B
- KNSA 1.6B
- IPO Year
- KRNT 2015
- KNSA 2018
- Fundamental
- Price
- KRNT $16.81
- KNSA $21.76
- Analyst Decision
- KRNT Strong Buy
- KNSA Strong Buy
- Analyst Count
- KRNT 5
- KNSA 6
- Target Price
- KRNT $34.00
- KNSA $37.17
- AVG Volume (30 Days)
- KRNT 299.6K
- KNSA 534.6K
- Earning Date
- KRNT 05-07-2025
- KNSA 04-22-2025
- Dividend Yield
- KRNT N/A
- KNSA N/A
- EPS Growth
- KRNT N/A
- KNSA N/A
- EPS
- KRNT N/A
- KNSA N/A
- Revenue
- KRNT $203,825,000.00
- KNSA $423,239,000.00
- Revenue This Year
- KRNT $11.22
- KNSA $37.21
- Revenue Next Year
- KRNT $12.76
- KNSA $2.58
- P/E Ratio
- KRNT N/A
- KNSA N/A
- Revenue Growth
- KRNT N/A
- KNSA 56.60
- 52 Week Low
- KRNT $13.59
- KNSA $16.56
- 52 Week High
- KRNT $34.29
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- KRNT 24.10
- KNSA 47.60
- Support Level
- KRNT $18.70
- KNSA $22.62
- Resistance Level
- KRNT $19.60
- KNSA $23.42
- Average True Range (ATR)
- KRNT 1.03
- KNSA 0.67
- MACD
- KRNT -0.15
- KNSA -0.25
- Stochastic Oscillator
- KRNT 0.22
- KNSA 14.57
About KRNT Kornit Digital Ltd.
Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.